Evidence map›Paper›PMID 39931952›Full record

ArticleEuropean journal of histochemistry : EJH2025

Exploring the efficacy of AMACR, ERG, and AR immunostains in prostatic adenocarcinoma and their association with novel grade groups.

Mohamed O Andarawi, Hassan Otifi, Hesham Hassan, Adil A Yousif, Saadalnour A Mustafa, Shawgi A Elsiddig, Asad Ma Babker, Elryah I Ali, Omer Osman Elhag

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of histochemistry : EJH, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohamed O AndarawiPathology Department, College of Medicine, King Khalid University, Abha.ORCID 0000-0002-9027-8449
Hassan OtifiPathology Department, College of Medicine, King Khalid University, Abha.
Hesham HassanPathology Department, College of Medicine, King Khalid University, Abha.
Adil A YousifDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha.ORCID 0009-0004-2438-0367
Saadalnour A MustafaDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University.
Shawgi A ElsiddigClinical Laboratory Sciences Department, College of Applied Medical Sciences, Jouf University, Sakaka.
Asad Ma BabkerDepartment of Medical Laboratory Sciences, College of Health Sciences, Gulf Medical University, Ajman.
Elryah I AliDepartment of Medical Laboratory Technology, College of Applied Medical Sciences, Northern Border University, Arar.ORCID 0000-0002-7444-0944
Omer Osman ElhagDepartment of Histopathology and Cytology, Faculty of Medical Laboratory Sciences, Omdurman Islamic University.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study examines the utility of AMACR, ERG, and AR immunostains in diagnosing prostatic adenocarcinoma (PCa) and assessing prognosis in comparison to the Gleason score and new WHO grading groups. Seventeen PCa biopsies and five benign prostatic hyperplasia (BPH) biopsies were analyzed. Immunoreactivity, scored from 1 to 3 based on percentage of positive cells and intensity of expression, was assessed, revealing 76.47% positivity for AMACR, 35.29% for ERG, and 94.12% for AR in PCa cases, with variable scores and intensity among markers and grade groups. AMACR sensitivity and ERG specificity were noted. Higher-grade PCa exhibited increased positivity for both markers, indicating prognostic significance. In BPH cases, AMACR showed positivity in 2 cases, ERG in 1, and AR in all cases, albeit with lower expression. Differential expression was observed among immunomarkers and grade groups of malignancy. AMACR and ERG stains serve as sensitive and specific markers for PCa diagnosis and prognosis. Their increasing positivity with higher-grade groups underscores prognostic value. These findings highlight the importance of immunostains in refining PCa diagnosis and prognostication.

Indexed as

AdenocarcinomaBiomarkers, TumorProstatic NeoplasmsRacemases and EpimerasesReceptors, AndrogenTranscriptional Regulator ERGAgedHumansImmunohistochemistryMaleMiddle AgedNeoplasm Gradingalpha-methylacyl-CoA racemaseAR protein, humanBiomarkers, TumorERG protein, humanRacemases and EpimerasesReceptors, AndrogenTranscriptional Regulator ERG

Identifiers

PMID39931952
PMCPMC11864098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.